Pulse Biosciences, Clayman Thyroid Center announce nPulse Vybrance commercial and clinical partnership

PULSE BIOSCIENCES, INC.

Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida is now treating patients with the nPulse Vybrance Percutaneous Electrode System for symptomatic benign thyroid nodules.
Clayman is the only site in the Tampa Bay Area offering nPulse technology; the rollout is part of Pulse Biosciences' controlled market development strategy.
Clinical collaboration covers real-world outcomes collection and formal studies of nsPFA energy in benign thyroid nodule treatment; no financial terms disclosed.
CEO Paul LaViolette said Clayman is one of the largest thyroid surgery centers nationally with significant regional and national referral patterns.
Vybrance delivers nonthermal nanosecond pulsed field ablation under ultrasound guidance; patients go home same day and symptoms typically ease within weeks.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.